You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePirenzepine
Accession NumberDB00670  (APRD00515)
TypeSmall Molecule
GroupsApproved
DescriptionAn antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as cimetidine and ranitidine. It is generally well tolerated by patients. [PubChem]
Structure
Thumb
Synonyms
11-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one
Pirenzepin
Pirenzepina
Pirenzépine
Pirenzepinum
External Identifiers
  • L-S519
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Gastrozepin Tab 50mgtablet50 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1984-12-311996-09-09Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnquweiPanion & BF
FolinzepinTsuruhara Seiyaku
GarendopineChoseido Pharmaceutical
GaspinGentle
GastrozepinBoehringer Ingelheim
GastsionShiono Kemikaru
GaszepinSwiss Pharm
KaroderinNippon Chemiphar
KawaipinSiu Guan
KiccalzinTakata Seiyaku
LizepineHealth Chemical
LonzepinLi Ta
MuszepinRoyal
PilenzelTaiyo Pharmaceutical
PinTatsumi Kagaku
PirepineYu Sheng
PirodeineMedisa Shinyaku
PizepineYuan Chou
RanclicTowa Yakuhin
RegastricJinup
StomazepinTaisho Yakuhin
UlopinePanbiotic
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Pirenzepine Hydrochloride
ThumbNot applicableDBSALT001002
Categories
UNII3G0285N20N
CAS number28797-61-7
WeightAverage: 351.4023
Monoisotopic: 351.169524941
Chemical FormulaC19H21N5O2
InChI KeyInChIKey=RMHMFHUVIITRHF-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26)
IUPAC Name
2-[2-(4-methylpiperazin-1-yl)acetyl]-2,4,9-triazatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one
SMILES
CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Pyrido-para-diazepine
  • N-piperazineacetamide
  • Alpha-amino acid or derivatives
  • N-alkylpiperazine
  • N-methylpiperazine
  • Para-diazepine
  • Imidolactam
  • Benzenoid
  • Pyridine
  • Piperazine
  • 1,4-diazinane
  • Heteroaromatic compound
  • Vinylogous amide
  • Tertiary carboxylic acid amide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of peptic ulcer, gastric ulcer, and duodenal ulcer.
PharmacodynamicsPirenzepine belongs to a group of medications called antispasmodics/anticholinergics. These medications are used to relieve cramps or spasms of the stomach, intestines, and bladder. Pirenzepine is used to treat duodenal or stomach ulcers or intestine problems. It can be used together with antacids or other medicine in the treatment of peptic ulcer. It may also be used to prevent nausea, vomiting, and motion sickness.
Mechanism of actionPirenzepine is a muscarinic receptor antagonist and binds to the muscarinic acetylcholine receptor. The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Pirenzepine Action PathwayDrug actionSMP00246
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9917
Blood Brain Barrier+0.9737
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8101
P-glycoprotein inhibitor IInhibitor0.5362
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterInhibitor0.5983
CYP450 2C9 substrateNon-substrate0.7426
CYP450 2D6 substrateNon-substrate0.5571
CYP450 3A4 substrateSubstrate0.6503
CYP450 1A2 substrateInhibitor0.5788
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.8814
CYP450 3A4 inhibitorNon-inhibitor0.8958
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.5
CarcinogenicityNon-carcinogens0.946
BiodegradationNot ready biodegradable0.9839
Rat acute toxicity1.8779 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6797
hERG inhibition (predictor II)Non-inhibitor0.5475
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral50 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP0.6Not Available
Caco2 permeability-6.36ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.682 mg/mLALOGPS
logP1.26ALOGPS
logP0.85ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)9.57ChemAxon
pKa (Strongest Basic)7.59ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area68.78 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity100.93 m3·mol-1ChemAxon
Polarizability37.11 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Czepita D: [Fundamentals of modern treatment of myopia]. Ann Acad Med Stetin. 2005;51(2):5-9. [PubMed:16519089 ]
External Links
ATC CodesA02BX03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (36.5 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with 1,10-Phenanthroline.
AclidiniumAclidinium may increase the anticholinergic activities of Pirenzepine.
AclidiniumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Aclidinium.
AlfentanilThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Alphacetylmethadol.
AmbenoniumThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Ambenonium.
AminophyllineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Aminophylline.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pirenzepine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Atracurium besylate.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Pirenzepine.
BenactyzineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Pirenzepine.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pirenzepine.
BezitramideThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Biperiden.
Botulinum Toxin Type APirenzepine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BPirenzepine may increase the anticholinergic activities of Botulinum Toxin Type B.
BuprenorphineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Buprenorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Butorphanol.
CarfentanilThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Carfentanil.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Pirenzepine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Chlorphenoxamine.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Pirenzepine.
CimetropiumPirenzepine may increase the anticholinergic activities of Cimetropium.
ClozapineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Clozapine.
CodeineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Codeine.
CoumaphosThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Coumaphos.
CyclopentolateThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Cyclopentolate.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pirenzepine.
DecamethoniumThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Decamethonium.
DemecariumThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Demecarium.
DesloratadineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Desloratadine.
DexetimideThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dexetimide.
DextromoramideThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dezocine.
DichlorvosThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dicyclomine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydromorphine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Diphenoxylate.
DonepezilThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Donepezil.
DPDPEThe risk or severity of adverse effects can be increased when Pirenzepine is combined with DPDPE.
DronabinolPirenzepine may increase the tachycardic activities of Dronabinol.
DyphyllineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Dyphylline.
EchothiophateThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Edrophonium.
EluxadolinePirenzepine may increase the constipating activities of Eluxadoline.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Pirenzepine.
EthylmorphineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Ethylmorphine.
EtorphineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Etorphine.
FentanylThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Fentanyl.
FenthionThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Fenthion.
FesoterodineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Fesoterodine.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Pirenzepine.
GalantamineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pirenzepine.
Ginkgo bilobaThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Pirenzepine.
GlycopyrroniumPirenzepine may increase the anticholinergic activities of Glycopyrronium.
HeroinThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Hexamethonium.
HomatropineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pirenzepine.
HydrocodoneThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydrocodone.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Pirenzepine.
HydromorphoneThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydromorphone.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pirenzepine.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Pirenzepine.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pirenzepine.
IsoflurophateThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Isoflurophate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Pirenzepine.
KetobemidoneThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Ketobemidone.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Levorphanol.
LofentanilThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Lofentanil.
MalathionThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Malathion.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pirenzepine.
MefloquineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Mefloquine.
MemantineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Memantine.
MethadonePirenzepine may increase the central nervous system depressant (CNS depressant) activities of Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Methantheline.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Pirenzepine.
MetixeneThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Metixene.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Pirenzepine.
MianserinMianserin may increase the anticholinergic activities of Pirenzepine.
MinaprineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Minaprine.
MirabegronThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Mirabegron.
MorphineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Morphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Pirenzepine is combined with N-butylscopolammonium bromide.
NabilonePirenzepine may increase the tachycardic activities of Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Nalbuphine.
NeostigmineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Neostigmine.
NormethadoneThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Normethadone.
NVA237The risk or severity of adverse effects can be increased when Pirenzepine is combined with NVA237.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pirenzepine.
OpiumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Orphenadrine.
OxybutyninThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pirenzepine.
PancuroniumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pancuronium.
PentazocineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pentazocine.
PentoliniumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pentolinium.
PethidineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pethidine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Pirenzepine.
PhysostigmineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Physostigmine.
PipecuroniumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pipecuronium.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Pirenzepine.
Potassium ChloridePirenzepine may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Pirenzepine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pirenzepine.
PropanthelineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Propantheline.
PyridostigmineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Pyridostigmine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Pirenzepine.
QuinidineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Quinidine.
RamosetronPirenzepine may increase the constipating activities of Ramosetron.
RemifentanilThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Remifentanil.
RivastigmineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Rivastigmine.
ScopolamineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Scopolamine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Scopolamine butylbromide.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Pirenzepine.
Sodium oxybatePirenzepine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Solifenacin.
SufentanilThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Sufentanil.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pirenzepine.
TacrineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Tacrine.
TapentadolThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tapentadol.
TeduglutideThe serum concentration of Pirenzepine can be increased when it is combined with Teduglutide.
TheophyllineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Theophylline.
TiotropiumPirenzepine may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Pirenzepine.
TolterodineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tolterodine.
TopiramateThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tramadol.
TrichlorfonThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Pirenzepine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pirenzepine.
TrimethaphanThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Trimethaphan.
TropicamideThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tropicamide.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Pirenzepine.
TubocurarineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tubocurarine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Pirenzepine.
UmeclidiniumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Umeclidinium.
VecuroniumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Vecuronium.
Food Interactions
  • Take 30 minutes before breakfast and at bedtime.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Pedretti RF, Prete G, Foreman RD, Adamson PB, Vanoli E: Autonomic modulation during acute myocardial ischemia by low-dose pirenzepine in conscious dogs with a healed myocardial infarction: a comparison with beta-adrenergic blockade. J Cardiovasc Pharmacol. 2003 May;41(5):671-7. [PubMed:12717096 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23